Prostate and other male cancers:
Indications for: CAMCEVI
Advanced prostate cancer.
Adult Dosage:
Give by SC inj on the upper- or mid-abdominal area. Avoid areas with brawny or fibrous tissue or locations that could be rubbed or compressed. 42mg once every 6months.
Children Dosage:
Not established.
CAMCEVI Contraindications:
Hypersensitivity to GnRH analogues.
CAMCEVI Warnings/Precautions:
May worsen metastatic vertebral lesions and/or urinary tract obstruction; monitor closely during first few weeks. Increased risk of diabetes, MI, sudden cardiac death, stroke. Monitor blood glucose, HbA1c, and for CVD signs/symptoms during therapy. Risk of QT prolongation in those with congenital long QT syndrome, CHF, or frequent electrolyte abnormalities. Correct and monitor electrolyte abnormalities; consider monitoring ECGs. Monitor serum testosterone levels post-inj. Embryo-fetal toxicity. Pregnancy. Nursing mothers: not recommended.
CAMCEVI Classification:
GnRH analogue.
CAMCEVI Interactions:
Caution with concomitant drugs known to prolong the QT interval.
Adverse Reactions:
Hot flush, hypertension, inj site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, pain in extremity; spinal cord compression, hyperglycemia, convulsions.
Generic Drug Availability:
NO
How Supplied:
Kit—1 (w. supplies)
